Nomogram models predicting prognosis for patients with t(8;21) acute myeloid leukemia: a SEER-based study.

Autor:	Yang J; Department of Hematology and Oncology, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, People's Republic of China., Zhu X; Department of Hematology and Oncology, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, People's Republic of China., Zhang H; Department of Hematology and Oncology, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, People's Republic of China., Fu Y; Department of Hematology and Oncology, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, People's Republic of China., Li Z; Department of Hematology and Oncology, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, People's Republic of China., Xing Z; Department of Hematology and Oncology, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, People's Republic of China., Yu Y; Department of Hematology and Oncology, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, People's Republic of China., Cao P; Department of Hematology and Oncology, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, People's Republic of China., Le J; Department of Hematology and Oncology, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, People's Republic of China., Jiang J; Department of Hematology and Oncology, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, People's Republic of China., Li J; Department of Hematology and Oncology, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, People's Republic of China., Wang H; Department of Hematology and Oncology, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, People's Republic of China., Qian M; Institute of Pediatrics and Department of Hematology and Oncology, Children's Hospital of Fudan University, National Children's Medical Center, and the Shanghai Key Laboratory of Medical Epigenetics, International Co-Laboratory of Medical Epigenetics and Metabolism (Ministry of Science and Technology), Institutes of Biomedical Sciences, Fudan University, Shanghai, People's Republic of China., Zhai X; Department of Hematology and Oncology, National Children's Medical Center, Children's Hospital of Fudan University, Shanghai, People's Republic of China.
Jazyk:	angličtina
Zdroj:	Hematology (Amsterdam, Netherlands) [Hematology] 2024 Dec; Vol. 29 (1), pp. 2381169. Date of Electronic Publication: 2024 Jul 24.
DOI:	10.1080/16078454.2024.2381169
Abstrakt:	Background: Acute myeloid leukemia (AML) with t(8;21) manifests as a diverse hematological malignancy. Although it was categorized into a favorable subtype, 30-40% of patients experience relapse. The objective of this research was to devise a nomogram for the accurate anticipation of both overall survival (OS) and cancer-specific survival (CSS) in t(8;21) AML. Methods: From the Surveillance, Epidemiology, and End Results (SEER) database, individuals diagnosed with t(8;21) AML from 2000 to 2018 were selected. Prognostic factors for t(8;21) AML were identified using Cox regression analysis and Akaike Information Criterion (AIC), forming the basis for constructing prognostic nomograms. Results: Key variables, including first primary tumor, age group, race, and chemotherapy, were identified and integrated into the nomogram. The C-index values for the nomograms predicting OS and CSS were 0.753 (validation: 0.765) and 0.764 (validation: 0.757), respectively. Ultimately, based on nomogram scores, patients were stratified into high-risk and low-risk groups, revealing significant disparities in both OS and CSS between these groups ( P  < 0.001). Conclusion: This study innovatively crafted nomograms, incorporating clinical and therapeutic variables, to forecast the 1-, 3-, and 5-year survival rates for individuals with t(8;21) AML.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu